All News

While scientists know more about the HIV infection than ever, and can prevent it from progressing into AIDS, there is still no known cure for the virus.

Top news of the day from across the health care landscape.

Technological advances have widened the potential solutions to improve adherence to high-cost specialty drugs.

Top news of the day from across the health care landscape.

It’s our job to spend as much time as it takes to help patients feel comfortable with the medications they are taking.

Top news of the week from Specialty Pharmacy Times.

Immunotherapy was first linked to cancer treatment in the late 19th century when surgeon William Coley discovered that the injection of bacteria into sarcoma sites led to tumor shrinkage.

The FDA advises health care providers to counsel patients receiving alemtuzumab on symptoms related to stroke and arterial dissection.

Epstein-Barr virus and Kaposi's sarcoma herpesvirus can activate and lead to the growth of cancerous cells.

Officials with the FDA have approved rituximab-abbs (Truxima, Celltrion) as a biosimilar to Rituxan (Genentech), making it the first biosimilar for the treatment of adult patients with non-Hodgkin’s lymphoma.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

Your residency cover letter might be the most challenging part of the whole application process.

New platform would allow health care providers in developing nations to perform easy HIV testing and monitoring.

The drug’s application was designated for fast track and priority review, as well as orphan product status.

The drug’s application was designated for fast track and priority review, as well as orphan product status.

Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018, thus far.

Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018 thus far.

CVS Health announced that it has closed its acquisition of Aetna with the promise to transform the consumer health experience.

CVS Health announced that it has finalized its acquisition of Aetna with the promise to transform the consumer health experience.

CVS Health announced that it has finalized its acquisition of Aetna, representing another example of the shift toward major vertical consolidation in the health care industry.

Both actions follow similar recalls of valsartan-containing products by other manufacturers.

Top news of the day from across the health care landscape.

Amazon’s entry into the pharmacy space could be the start of significant changes in the specialty space.

Top news of the day from across the health care landscape.

Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine/Valsartan combination tablets and Amlodipine Valsartan/Hydrochlorothiazide combination tablets, due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India.

The Task Force notes in the draft recommendations that clinicians should screen everyone between the ages 15 to 65 years and all pregnant women for HIV.

Fostemsavir (ViiV Healthcare) may be a potential new option for patients with HIV who have become resistant to other medications.